Who are erythromycin [Eritex]'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Linezolid antimicrobial-lock solution, Erythromycin, Azithromycin , Clarithromycin, AzaSite®, Azithropycin according to symptoms, FMS azithromycin tablets, Azithromycin Ophthalmic Solution, 1%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/erythromycin-eritex.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

erythromycin [Eritex] — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

erythromycin [Eritex] (erythromycin [Eritex]) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: macrolide antibiotic. Area: Infectious diseases.

phase 3 macrolide antibiotic 50S ribosomal subunit Infectious diseases Small molecule Live · refreshed every 30 min

Target snapshot

erythromycin [Eritex] (erythromycin [Eritex]) — Hoffmann-La Roche. Erythromycin inhibits protein synthesis by binding to the 50S subunit of the bacterial ribosome.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
erythromycin [Eritex] TARGET	erythromycin [Eritex]	Hoffmann-La Roche	phase 3	macrolide antibiotic	50S ribosomal subunit
Linezolid antimicrobial-lock solution	Linezolid antimicrobial-lock solution	Clinica Universidad de Navarra, Universidad de Navarra	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit
Erythromycin, Azithromycin , Clarithromycin	Erythromycin, Azithromycin , Clarithromycin	Baqiyatallah Medical Sciences University	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
AzaSite®	AzaSite®	Merck Sharp & Dohme LLC	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Azithropycin according to symptoms	Azithropycin according to symptoms	University Hospital, Montpellier	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit (23S rRNA)
FMS azithromycin tablets	FMS azithromycin tablets	University of Taubate	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Azithromycin Ophthalmic Solution, 1%	Azithromycin Ophthalmic Solution, 1%	Merck Sharp & Dohme LLC	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (macrolide antibiotic class)

Hoffmann-La Roche · 1 drug in this class
RDC Clinical Pty Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). erythromycin [Eritex] — Competitive Intelligence Brief. https://druglandscape.com/ci/erythromycin-eritex. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing